Agomelatine

DB06594ApprovedInvestigationalSmall molecule

Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine... Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005.

Chemical structure of Agomelatine
Mechanism
Curator reviewed
Primary indication
Agomelatine is indicated to treat major depressive episodes in adults.Curator reviewed · 1 structured indication
Formula / weight
C15H17NO2 · 243.301 g/mol (avg)
First approval
European Union, 2020
Code names
AGO-178 · AGO178C · S-20098
Brand names
  • Valdoxan

Resolves to

Compound
UNII137R1N49ADCAS138112-76-2ChEMBLCHEMBL10878ChEBI134990PubChem82148KEGGD02578
Clinical / RWD
ATCN06AX22PharmGKBPA165958363
Structure
InChIKeyYJYPHIXNFHFHND-UHFFFAOYSA-NSMILESCOC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Targets
P28335HTR2CP48039MTNR1AP49286MTNR1B

What you can answer from here — as of June 25, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,036Drug interactionsStructured to mechanism, not free text
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
104Marketed productsAcross 10 countries and 15 labellers
Sign in
1ATC codeIncluding every combination product, plus 18 drug categories
Sign in
20+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Agomelatine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In